Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia

Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia

The paper considers whether a current treatment option for rheumatoid arthritis with genetically engineered biological agents that selectively block the activity of individual proinflammatory mediators and cell surface antigens involved in autoimmune inflammation may be performed in Karelia, which c...

Full description

Bibliographic Details
Main Author: Irina Mikhailovna Marusenko
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2013-12-01
Series:Современная ревматология
Subjects:
genetically engineered biological agents
infliximab
monoclonal antibodies
rheumatoid arthritis
rituximab
tumor necrosis factor-α
Online Access:https://mrj.ima-press.net/mrj/article/view/534
id doaj-ffe47e33567e4b80842c0a3466d389b1
record_format Article
spelling doaj-ffe47e33567e4b80842c0a3466d389b12021-07-29T09:00:08ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2013-12-01749710010.14412/1996-7012-2013-24461839Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of KareliaIrina Mikhailovna Marusenko0Petrozavodsk State University, Ministry of Health of RussiaThe paper considers whether a current treatment option for rheumatoid arthritis with genetically engineered biological agents that selectively block the activity of individual proinflammatory mediators and cell surface antigens involved in autoimmune inflammation may be performed in Karelia, which can achieve control of the disease, retard its progression, and improve prognosis.https://mrj.ima-press.net/mrj/article/view/534genetically engineered biological agentsinfliximabmonoclonal antibodiesrheumatoid arthritisrituximabtumor necrosis factor-α
collection DOAJ
language Russian
format Article
sources DOAJ
author Irina Mikhailovna Marusenko
spellingShingle Irina Mikhailovna Marusenko
Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
Современная ревматология
genetically engineered biological agents
infliximab
monoclonal antibodies
rheumatoid arthritis
rituximab
tumor necrosis factor-α
author_facet Irina Mikhailovna Marusenko
author_sort Irina Mikhailovna Marusenko
title Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
title_short Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
title_full Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
title_fullStr Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
title_full_unstemmed Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
title_sort rheumatoid arthritis therapy with genetically engineered biological agents in the republic of karelia
publisher IMA-PRESS LLC
series Современная ревматология
issn 1996-7012
2310-158X
publishDate 2013-12-01
description The paper considers whether a current treatment option for rheumatoid arthritis with genetically engineered biological agents that selectively block the activity of individual proinflammatory mediators and cell surface antigens involved in autoimmune inflammation may be performed in Karelia, which can achieve control of the disease, retard its progression, and improve prognosis.
topic genetically engineered biological agents
infliximab
monoclonal antibodies
rheumatoid arthritis
rituximab
tumor necrosis factor-α
url https://mrj.ima-press.net/mrj/article/view/534
work_keys_str_mv AT irinamikhailovnamarusenko rheumatoidarthritistherapywithgeneticallyengineeredbiologicalagentsintherepublicofkarelia
_version_ 1721250341756862464

Similar Items